Blood test could predict who benefits from cancer immunotherapy
NCT ID NCT05091190
Summary
This study aims to find a better way to predict which patients with advanced lung or head and neck cancer will respond to immunotherapy. Researchers will collect blood samples from 75 participants before and during their standard immunotherapy treatment. They will measure how quickly the body clears the drug and track cancer cells in the blood to see if these factors correlate with treatment success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Croix Rousse Hospital
Lyon, France
-
Lyon Sud Hospital
Pierre-Bénite, France
Conditions
Explore the condition pages connected to this study.